IM Cannabis (IMCC) Net Income towards Common Stockholders (2019 - 2026)
IM Cannabis (IMCC) posted quarterly Net Income towards Common Stockholders of -$1.8 million for Q1 2026, down 1575.03% year-over-year from $121960.4 in Q1 2025, and up 83.28% quarter-over-quarter from -$10.8 million in Q4 2025.
IM Cannabis (IMCC) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
IM Cannabis' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$1.8 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 1575.03% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at -$11.1 million (up 42.08% YoY), while the FY2025 annual figure was -$8.1 million, down 4.99% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$1.8 million, up from -$10.8 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $2.7 million in Q3 2025, with the low at -$94.8 million in Q3 2022.
- The 5-year median for Net Income towards Common Stockholders is -$1.8 million (2026), against an average of -$9.4 million.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders slumped 2124020250.79% in 2024, then jumped 492.52% in 2025.
- IM Cannabis' Net Income towards Common Stockholders stood at -$15.6 million in 2022, then gained by 17.35% to -$12.9 million in 2023, then slipped by 11.61% to -$14.4 million in 2024, then advanced by 25.44% to -$10.8 million in 2025, then surged by 83.28% to -$1.8 million in 2026.
- Business Quant data shows IMCC's Net Income towards Common Stockholders at -$1.8 million in Q1 2026, -$10.8 million in Q4 2025, and $2.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | IM Cannabis | 554,496.00 | -614,474.17 | 1.09 Mn | -3.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.15 Mn |
| Mar 31, 2026 | -1.80 Mn |
| Dec 31, 2025 | -10.76 Mn |
| Sep 30, 2025 | 2.65 Mn |
| Jun 30, 2025 | -1.16 Mn |
| Mar 31, 2025 | 121,960.38 |
| Dec 31, 2024 | -14.43 Mn |
| Sep 30, 2024 | -675,875.24 |
| Jun 30, 2024 | -4.11 Mn |
| Mar 31, 2024 | -4.47 Mn |
| Dec 31, 2023 | -12.93 Mn |
| Sep 30, 2023 | 1.59 Mn |
| Jun 30, 2023 | 0.19 |
| Mar 31, 2023 | -664,247.34 |
| Dec 31, 2022 | -15.64 Mn |
| Sep 30, 2022 | -94.80 Mn |
| Jun 30, 2022 | -2.45 |
| Mar 31, 2022 | -2.89 Mn |
| Dec 31, 2021 | -24.46 Mn |
| Sep 30, 2021 | 5.15 Mn |